These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 18383887)
1. Expression of maspin in papillary Ta/T1 bladder neoplasms. Blandamura S; D'Alessandro E; Giacomelli L; Guzzardo V; Battanello W; Repele M; Ninfo V Anticancer Res; 2008; 28(1B):471-8. PubMed ID: 18383887 [TBL] [Abstract][Full Text] [Related]
2. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis. Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745 [TBL] [Abstract][Full Text] [Related]
3. Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder. Ramos D; Navarro S; Villamón R; Gil-Salom M; Llombart-Bosch A Cancer; 2003 Apr; 97(8):1876-83. PubMed ID: 12673713 [TBL] [Abstract][Full Text] [Related]
4. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Desai S; Lim SD; Jimenez RE; Chun T; Keane TE; McKenney JK; Zavala-Pompa A; Cohen C; Young RH; Amin MB Mod Pathol; 2000 Dec; 13(12):1315-23. PubMed ID: 11144928 [TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Wild PJ; Herr A; Wissmann C; Stoehr R; Rosenthal A; Zaak D; Simon R; Knuechel R; Pilarsky C; Hartmann A Clin Cancer Res; 2005 Jun; 11(12):4415-29. PubMed ID: 15958626 [TBL] [Abstract][Full Text] [Related]
6. Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Marioni G; Blandamura S; Giacomelli L; Calgaro N; Segato P; Leo G; Fischetto D; Staffieri A; de Filippis C Histopathology; 2005 May; 46(5):576-82. PubMed ID: 15842640 [TBL] [Abstract][Full Text] [Related]
7. Maspin expression in adenocarcinoma of the ampulla of Vater: relation with clinicopathological parameters and apoptosis. Blandamura S; D'Alessandro E; Guzzardo V; Giacomelli L; Moschino P; Parenti A; Ninfo V Anticancer Res; 2007; 27(2):1059-65. PubMed ID: 17465244 [TBL] [Abstract][Full Text] [Related]
9. Nuclear localization of mammary serine protease inhibitor (MASPIN): is its impact on the prognosis in laryngeal carcinoma due to a proapoptotic effect? Marioni G; Giacomelli L; D'Alessandro E; Marchese-Ragona R; Staffieri C; Ferraro SM; Staffieri A; Blandamura S Am J Otolaryngol; 2008; 29(3):156-62. PubMed ID: 18439947 [TBL] [Abstract][Full Text] [Related]
10. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. Holmäng S; Andius P; Hedelin H; Wester K; Busch C; Johansson SL J Urol; 2001 Apr; 165(4):1124-8; discussion 1128-30. PubMed ID: 11257652 [TBL] [Abstract][Full Text] [Related]
11. Invasive urothelial carcinoma with chordoid features: a report of 12 distinct cases characterized by prominent myxoid stroma and cordlike epithelial architecture. Cox RM; Schneider AG; Sangoi AR; Clingan WJ; Gokden N; McKenney JK Am J Surg Pathol; 2009 Aug; 33(8):1213-9. PubMed ID: 19542871 [TBL] [Abstract][Full Text] [Related]
12. High Grade T1 Papillary Urothelial Bladder Cancer Shows Prominent Peritumoral Retraction Clefting. Džombeta T; Krušlin B Pathol Oncol Res; 2018 Jul; 24(3):567-574. PubMed ID: 28752222 [TBL] [Abstract][Full Text] [Related]
13. Outcome of very large superficial bladder tumours: a 10-year experience. Gupta SK; Parr NJ Scand J Urol Nephrol; 2008; 42(3):243-8. PubMed ID: 18432531 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973). March-Villalba JA; Ramos-Soler D; Soriano-Sarrió P; Hervás-Marín D; Martínez-García L; Martínez-Jabaloyas JM Urol Oncol; 2019 Feb; 37(2):158-165. PubMed ID: 30446453 [TBL] [Abstract][Full Text] [Related]
15. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma? Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253 [TBL] [Abstract][Full Text] [Related]